Literature DB >> 15466691

Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol.

Susan Schuval1, Russell B Van Dyke, Jane C Lindsey, Paul Palumbo, Lynne M Mofenson, James M Oleske, Joseph Cervia, Andrea Kovacs, Wayne N Dankner, Elizabeth Smith, Barbara Nowak, Gregory Ciupak, Nancy Webb, Michelle Eagle, Dorothy Smith, Roslyn Hennessey, Melissa Goodman-Kerkau, Myron J Levin.   

Abstract

OBJECTIVE: To evaluate the prevalence of hepatitis C virus (HCV) infection in children with perinatal human immunodeficiency virus (HIV) infection.
DESIGN: Cross-sectional substudy.
SETTING: Multicenter study from 41 sites in the United States. PATIENTS: Children with perinatal HIV infection were randomly selected from a large, long-term, follow-up protocol. MAIN OUTCOME MEASURE: Hepatitis C infection was defined as having positive test results on both HCV antibody and HCV RNA assays.
RESULTS: Five hundred thirty children enrolled in the substudy; definitive HCV test results were available for 525 children. Eighty-three percent were of a minority race or ethnicity. They were equally distributed by sex, had a median age of 10.7 years, and were relatively healthy, with 75% having CD4+ lymphocyte counts greater than 500 cells/mm3. Eight of 525 children (1.5%; 95% confidence interval [CI], 0.7%-3.0%) infected with HIV were coinfected with HCV. In contrast, the rate of HCV infection in a serosurvey of more than 2700 children aged 6 to 11 years from the National Health and Nutrition Examination Survey was 0.2% (95% CI, 0.04%-0.6%). In our study, there were no differences between children coinfected with HIV and HCV and those without HCV infection in terms of demographic characteristics, CD4+ or CD8+ T-lymphocyte counts, HIV 1 RNA levels, preterm or mode of delivery, or liver disease; however, the number of children coinfected with HIV and HCV was small.
CONCLUSION: While HCV prevalence infection rates are low in children with perinatal HIV infection, they are 8 to 10 times higher than reported in HCV serosurveys of children in the United States.

Entities:  

Mesh:

Year:  2004        PMID: 15466691     DOI: 10.1001/archpedi.158.10.1007

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  4 in total

1.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

2.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

3.  Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009.

Authors:  Shuntai Zhou; Yan Zhao; Yun He; Huiqin Li; Marc Bulterys; Xin Sun; Zhihui Dou; Matthew Robinson; Fujie Zhang
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

4.  Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.

Authors:  Mary Adetola Lawal; Oluwafunmilayo Funke Adeniyi; Patricia Eyanya Akintan; Abideen Olurotimi Salako; Olorunfemi Sunday Omotosho; Edamisan Olusoji Temiye
Journal:  PLoS One       Date:  2020-12-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.